Display options
Cite
Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm. 2017;4(3):e334doi: 10.1212/NXI.0000000000000334.
Oertel, F. C., Kuchling, J., Zimmermann, H., Chien, C., Schmidt, F., Knier, B., Bellmann-Strobl, J., Korn, T., Scheel, M., Klistorner, A., Ruprecht, K., Paul, F., & Brandt, A. U. (2017). Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurology(R) neuroimmunology & neuroinflammation, 4(3), e334. https://doi.org/10.1212/NXI.0000000000000334
Oertel, Frederike C, et al. "Microstructural visual system changes in AQP4-antibody-seropositive NMOSD." Neurology(R) neuroimmunology & neuroinflammation vol. 4,3 (2017): e334. doi: https://doi.org/10.1212/NXI.0000000000000334
Oertel FC, Kuchling J, Zimmermann H, Chien C, Schmidt F, Knier B, Bellmann-Strobl J, Korn T, Scheel M, Klistorner A, Ruprecht K, Paul F, Brandt AU. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm. 2017 Feb 22;4(3):e334. doi: 10.1212/NXI.0000000000000334. eCollection 2017 May. PMID: 28255575; PMCID: PMC5322864.
Copy Download .nbib Format: NLM
Share it on

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 22;4(3):e334. doi: 10.1212/NXI.0000000000000334. eCollection 2017 May.

Microstructural visual system changes in AQP4-antibody-seropositive NMOSD.

Neurology(R) neuroimmunology & neuroinflammation

Frederike C Oertel, Joseph Kuchling, Hanna Zimmermann, Claudia Chien, Felix Schmidt, Benjamin Knier, Judith Bellmann-Strobl, Thomas Korn, Michael Scheel, Alexander Klistorner, Klemens Ruprecht, Friedemann Paul, Alexander U Brandt

Affiliations

  1. NeuroCure Clinical Research Center (F.C.O., J.K., H.Z., C.C., F.S., J.B.-S., M.S., F.P., A.U.B.), and Department of Neurology (J.K., F.S., J.B.-S., K.R., F.P.), Charité-Universitätsmedizin Berlin; Department of Neurology (B.K., T.K.), Klinikum rechts der Isar, and Department of Experimental Neuroimmunology (T.K.), Technische Universität München; Munich Cluster for Systems Neurology (SyNergy) (T.K.), Germany; Clinical Ophthalmology and Eye Health (A.K.), Central Clinical School, Save Sight Institute, Sydney, Australia; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany.

PMID: 28255575 PMCID: PMC5322864 DOI: 10.1212/NXI.0000000000000334

Abstract

OBJECTIVE: To trace microstructural changes in patients with aquaporin-4 antibody (AQP4-ab)-seropositive neuromyelitis optica spectrum disorders (NMOSDs) by investigating the afferent visual system in patients without clinically overt visual symptoms or visual pathway lesions.

METHODS: Of 51 screened patients with NMOSD from a longitudinal observational cohort study, we compared 6 AQP4-ab-seropositive NMOSD patients with longitudinally extensive transverse myelitis (LETM) but no history of optic neuritis (ON) or other bout (NMOSD-LETM) to 19 AQP4-ab-seropositive NMOSD patients with previous ON (NMOSD-ON) and 26 healthy controls (HCs). Foveal thickness (FT), peripapillary retinal nerve fiber layer (pRNFL) thickness, and ganglion cell and inner plexiform layer (GCIPL) thickness were measured with optical coherence tomography (OCT). Microstructural changes in the optic radiation (OR) were investigated using diffusion tensor imaging (DTI). Visual function was determined by high-contrast visual acuity (VA). OCT results were confirmed in a second independent cohort.

RESULTS: FT was reduced in both patients with NMOSD-LETM (

CONCLUSIONS: Patients with AQP4-ab-seropositive NMOSD without a history of ON have microstructural changes in the afferent visual system. The localization of retinal changes around the Müller-cell rich fovea supports a retinal astrocytopathy.

References

  1. Prog Retin Eye Res. 2006 Jul;25(4):397-424 - PubMed
  2. Neurology. 2007 Feb 20;68(8):603-5 - PubMed
  3. Neuroimage. 2007 May 1;35(4):1459-72 - PubMed
  4. Brain. 2007 May;130(Pt 5):1224-34 - PubMed
  5. Neurology. 2007 Dec 11;69(24):2221-31 - PubMed
  6. Br J Ophthalmol. 2012 Jan;96(1):62-7 - PubMed
  7. Brain. 2012 Feb;135(Pt 2):521-33 - PubMed
  8. Neuroimage. 2012 Feb 15;59(4):3173-7 - PubMed
  9. Neuroimage. 2012 Feb 15;59(4):3774-83 - PubMed
  10. Mult Scler. 2012 Jul;18(7):1013-21 - PubMed
  11. Radiology. 2012 Apr;263(1):235-42 - PubMed
  12. Prog Retin Eye Res. 2013 Jul;35:63-81 - PubMed
  13. PLoS One. 2013 Jun 21;8(6):e66151 - PubMed
  14. PLoS One. 2013 Jun 18;8(6):e66271 - PubMed
  15. Brain Pathol. 2014 Jan;24(1):83-97 - PubMed
  16. Clin Exp Immunol. 2014 May;176(2):149-64 - PubMed
  17. Mult Scler. 2015 Jun;21(7):925-34 - PubMed
  18. Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62 - PubMed
  19. Neurology. 2015 Mar 17;84(11):1165-73 - PubMed
  20. PLoS One. 2015 Mar 05;10(3):e0118948 - PubMed
  21. JAMA Neurol. 2015 Jul;72(7):815-22 - PubMed
  22. Neurology. 2015 Jul 14;85(2):177-89 - PubMed
  23. Mult Scler. 2016 Apr;22(4):470-82 - PubMed
  24. Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e110 - PubMed
  25. PLoS One. 2015 Sep 08;10(9):e0137316 - PubMed
  26. PLoS One. 2015 Sep 16;10(9):e0137064 - PubMed
  27. Acta Neuropathol Commun. 2015 Dec 04;3:82 - PubMed
  28. Neurol Neuroimmunol Neuroinflamm. 2016 Feb 02;3(2):e204 - PubMed
  29. Eur Radiol. 2016 Dec;26(12):4413-4422 - PubMed
  30. Exp Eye Res. 2016 May;146:259-68 - PubMed
  31. Brain Pathol. 2017 May;27(3):249-265 - PubMed
  32. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15 - PubMed
  33. J Neurol. 2016 Jul;263(7):1343-8 - PubMed
  34. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e224 - PubMed
  35. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 20;3(3):e229 - PubMed
  36. Neurology. 2016 Jun 14;86(24):2303-9 - PubMed
  37. Acta Neuropathol Commun. 2016 Aug 08;4(1):82 - PubMed
  38. J Neuroinflammation. 2016 Oct 20;13(1):275 - PubMed
  39. Neurol Neuroimmunol Neuroinflamm. 2016 Oct 24;3(6):e286 - PubMed
  40. J Neuroinflammation. 2016 Nov 1;13(1):282 - PubMed

Publication Types